Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 173.45 points (-1.1%) at 16,142 as of Wednesday, Oct. 15, 2014, 4:20 PM ET. The NYSE advances/declines ratio sits at 1,470 issues advancing vs. 1,677 declining with 92 unchanged.

The Health Care sector as a whole closed the day up 0.7% versus the S&P 500, which was down 0.8%. Top gainers within the Health Care sector included

Aurinia Pharmaceuticals

(

AUPH

), up 1.7%,

Aoxing Pharmaceutical

(

AXN

), up 3.2%,

Bio-Rad Laboratories

TheStreet Recommends

(

BIO.B

), up 7.3%,

Oragenics

(

OGEN

), up 2.0% and

ImmuCell

(

ICCC

), up 2.5%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the sector higher today:

Oragenics

(

OGEN

) is one of the companies that pushed the Health Care sector higher today. Oragenics was up $0.02 (2.0%) to $1.02 on average volume. Throughout the day, 20,393 shares of Oragenics exchanged hands as compared to its average daily volume of 16,800 shares. The stock ranged in a price between $0.99-$1.03 after having opened the day at $0.99 as compared to the previous trading day's close of $1.00.

Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. Oragenics has a market cap of $36.2 million and is part of the drugs industry. Shares are down 64.4% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates Oragenics a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Oragenics as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on OGEN go as follows:

  • OGEN's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 65.67%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income increased by 8.6% when compared to the same quarter one year prior, going from -$2.07 million to -$1.90 million.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ORAGENICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has increased to -$1.70 million or 15.15% when compared to the same quarter last year. Despite an increase in cash flow of 15.15%, ORAGENICS INC is still growing at a significantly lower rate than the industry average of 103.02%.
  • The gross profit margin for ORAGENICS INC is rather high; currently it is at 61.06%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -625.41% is in-line with the industry average.

You can view the full analysis from the report here:

Oragenics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close,

Aoxing Pharmaceutical

(

AXN

) was up $0.01 (3.2%) to $0.22 on light volume. Throughout the day, 7,040 shares of Aoxing Pharmaceutical exchanged hands as compared to its average daily volume of 34,900 shares. The stock ranged in a price between $0.21-$0.23 after having opened the day at $0.23 as compared to the previous trading day's close of $0.21.

Aoxing Pharmaceutical Company, Inc., a specialty pharmaceutical company, researches, develops, manufactures, and distributes various narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. Aoxing Pharmaceutical has a market cap of $13.1 million and is part of the drugs industry. Shares are down 15.0% year-to-date as of the close of trading on Tuesday. Currently there are no analysts who rate Aoxing Pharmaceutical a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Aoxing Pharmaceutical as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on AXN go as follows:

  • AXN's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 28.58%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The gross profit margin for AOXING PHARMACEUTICAL CO INC is rather high; currently it is at 58.33%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -71.80% is in-line with the industry average.
  • Net operating cash flow has significantly increased by 68.38% to -$0.56 million when compared to the same quarter last year. In addition, AOXING PHARMACEUTICAL CO INC has also vastly surpassed the industry average cash flow growth rate of -1.32%.
  • AOXING PHARMACEUTICAL CO INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. During the past fiscal year, AOXING PHARMACEUTICAL CO INC continued to lose money by earning -$0.16 versus -$0.34 in the prior year.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 78.4% when compared to the same quarter one year prior, rising from -$10.78 million to -$2.33 million.

You can view the full analysis from the report here:

Aoxing Pharmaceutical Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Aurinia Pharmaceuticals

(

AUPH

) was another company that pushed the Health Care sector higher today. Aurinia Pharmaceuticals was up $0.05 (1.7%) to $2.94 on heavy volume. Throughout the day, 1,973 shares of Aurinia Pharmaceuticals exchanged hands as compared to its average daily volume of 300 shares. The stock ranged in a price between $1.41-$2.95 after having opened the day at $2.35 as compared to the previous trading day's close of $2.89.

Aurinia Pharmaceuticals has a market cap of $97.6 million and is part of the drugs industry. Shares are down 6.3% year-to-date as of the close of trading on Tuesday.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.